Some experts look at Medical, Healthcare and Big Pharma shares as a commercial massacre, making them a safe haven amid uncertainty caused by Trump’s tariff. On April 8, the Mizuho Securities America’s strategy appeared in CNBC to talk about whether speculation about the health care sector is a safe haven during market disturbances. He also discussed the reason for the failure of health care companies to increase the respect of investors, given that health care is 20 % of the American economy, which translates into about 1/5 of the entire national product in the country.
Hulls said that health care companies and major pharmaceutical preparations in the country are undoubtedly helping to fight health care problems. However, when we look at their financial models and the way their business is currently being prepared, we have public patent slopes over the next 5-7 years in the medium term to the long term of the company, as well as price concessions with the Irish Republican Army and some of the things that the Biden administration has placed in its place. We have also got prices for the short term, and between these two competitions and other setbacks. Thus, the models are never well lined enough for investors who have a lot of confidence, as business models do not lend themselves in the long run. These are the main reasons that the sector and stocks offer for a long time.
Hulls also saw that managed care, especially government -focused names, are somewhat safe because they are isolated from customs tariffs as US -based companies. In fact, the economic slowdown is actually beneficial to them because they want less patience and patience through the system, which they usually overcome. He said that managed care is a good day, and investors may consider possessing some companies in this sector.
However, it is a relative game, where there are many different variables in playing, and investors play mainly from HOPSCotch in an attempt to jump from one region to another, whether it is a tariff, drug pricing or other public policies. He drew a picture similar to the inventory of medical devices centered around the United States. Thus, these two sectors have less risks for others, which makes them a fairly safe haven.
In this article, we first played back through the traded investment funds and financial media reports to collect an initial list of stocks. Then we examined the exclusive Monkey database of billionaire billionaires to choose the 10 best medical shares with the largest billions of investors. These billionaires are founders or managers of some leading hedge boxes in the world and companies.
Why are we interested in the arrows that accumulate hedge boxes? The reason is simple: Our research showed that we can outperform the market by imitating the best stock choices for the best hedge boxes. The quarterly newsletter strategy chooses 14 small stocks of large and large rule for each quarter and has returned 275 % since May 2014, overcoming its standard by 150 ° C (See more details here).
Is Intuity Surgical, Inc. (ISRG) are the most expensive arrows in March?
A medical team performs minimal gaseous surgery with a Da Vinci surgical system.
Invested billionaire number: 18
Number of hedge boxes: 95
At Intuity Surgical, Inc. (NASDAQ: ISRG) is an environmental system for services and products that provide surgical solutions with the help of mechanism and invasive care. Its products include Ion Endoluminal and Da Vinci Surgery. In 2024, INTUITIVE SURGICAL, Inc. (NASDAQ: ISRG) by expanding the base of its installed system to 9,902, which reflects 15 % growth. The number of procedures that were implemented also grew by 17 %, indicating the adoption of global technology.
Its financial results, Q4 2024, also showed significant growth, while increasing the DA VINCI procedures by 18 %. Total revenue also increased by 25 % to $ 2.41 billion, overcoming a consensus of $ 2.24 billion. Intuitive Surgan, Inc. (Nasdaq: ISRG) is an important place in the surgical robot market. According to Grand View Research, the surgical robot market is expected to grow at an annual growth rate of 9.5 % until 2030. The global market value is expected to be about $ 7.4 billion by that time, up from $ 4.3 billion in the past year. The market holds the ability to grow in the coming years and contracts, with the support of rapid progress of health care technologies.
Intuitive Surgan, Inc. (NASDAQ: ISRG) about her optimism for 2025, and expects 13 % -16 % growth in Da Vinci procedures around the world. In a report issued on April 2, Patrick Wood of Morgan Stanley maintained a purchase on Intuitive Surgical, Inc. (NASDAQ: ISRG) set a $ 650.00 targeted price. The company said that the growth in the company’s general surgery sector is more diverse than expected, which represents an attractive entry point for investors in conjunction with the decline of the last shares.
Generally, ISRG Third rank In the list of the best medical shares to buy according to billionaires. Although we acknowledge the possibility of ISRG as an investment, our condemnation lies in the belief that some artificial intelligence shares have a greater promise to provide higher returns and do so in a shorter time frame. Amnesty International has increased since the beginning of 2025, while famous artificial intelligence shares have lost about 25 %. If you are looking for the most promising Amnesty International share than ISRG but it is trading less than 5 times its profits, check our report on The cheapest inventory of artificial intelligence.
